Long-term results of radiofrequency and microwave ablation of colorectal cancer liver metastasis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Radiofrequency ablation (RFA) or microwave ablation (MWA) is effective for colorectal cancer liver metastases. We aimed to investigate the impact of different variables on survival. Methods: Sixty-four patients (142 lesions) who underwent thermoablation between January 2007 and January 2019 were retrospectively analyzed. The overall survival (OS) and liver progression-free survival (Li-PFS) were compared using Kaplan-Meier analysis. Univariable and multivariable Cox-regression were done to identify prognostic factors. Results: No significant difference was found between median OS (59.39 months) and Li-PFS (41.22 months) of patients who received MWA (n = 33); and median OS (61.00 months) and Li-PFS (53.43 months) of patients who received RFA (n = 31) (OS: P = 0.697; Li-PFS: P = 0.122). The median OS and Li-PFS were significantly decreased with lung metastases and K-ras mutations (P < 0.001). There was no correlation between prior systemic chemotherapy (n = 25) and both outcome parameters (OS: P = 0.613; Li-PFS: P = 0.665). No significant difference was observed in patients with lesions less than 30 mm diameter (n = 44) whether they received prior systemic chemotherapy (n = 17) or not (n = 27) (OS: P = 0.27; Li-PFS: P = 0.42). Similarly, in patients with a lesion of 3–5 cm diameter (n = 20; eight of them had prior chemotherapy), there was no correlation for both outcomes (OS: P = 0.069; Li-PFS: P = 0.71). The most important prognostic factor was concomitant lung metastases (hazard ratio = 3.689, P = 0.002). Conclusion: Concomitant lung metastasis and mutant K-ras were associated with shorter survival. Survival did not differ significantly regarding thermoablation technique or prior systemic chemotherapy. However, in the patient group with lung metastases, curative treatments had better survival than patients who received chemotherapy only. Additional therapeutic options should be considered in patients with concomitant lung metastasis.
Abstract
Background: Radiofrequency ablation (RFA) or microwave ablation (MWA) is effective for colorectal cancer liver metastases. We aimed to investigate the impact of different variables on survival. Methods: Sixty-four patients (142 lesions) who underwent thermoablation between January 2007 and January 2019 were retrospectively analyzed. The overall survival (OS) and liver progression-free survival (Li-PFS) were compared using Kaplan-Meier analysis. Univariable and multivariable Cox-regression were done to identify prognostic factors. Results: No significant difference was found between median OS (59.39 months) and Li-PFS (41.22 months) of patients who received MWA (n = 33); and median OS (61.00 months) and Li-PFS (53.43 months) of patients who received RFA (n = 31) (OS: P = 0.697; Li-PFS: P = 0.122). The median OS and Li-PFS were significantly decreased with lung metastases and K-ras mutations (P < 0.001). There was no correlation between prior systemic chemotherapy (n = 25) and both outcome parameters (OS: P = 0.613; Li-PFS: P = 0.665). No significant difference was observed in patients with lesions less than 30 mm diameter (n = 44) whether they received prior systemic chemotherapy (n = 17) or not (n = 27) (OS: P = 0.27; Li-PFS: P = 0.42). Similarly, in patients with a lesion of 3–5 cm diameter (n = 20; eight of them had prior chemotherapy), there was no correlation for both outcomes (OS: P = 0.069; Li-PFS: P = 0.71). The most important prognostic factor was concomitant lung metastases (hazard ratio = 3.689, P = 0.002). Conclusion: Concomitant lung metastasis and mutant K-ras were associated with shorter survival. Survival did not differ significantly regarding thermoablation technique or prior systemic chemotherapy. However, in the patient group with lung metastases, curative treatments had better survival than patients who received chemotherapy only. Additional therapeutic options should be considered in patients with concomitant lung metastasis.
참고문헌 (30)
- Engstrand J, "Colorectal cancer liver metastases-a population-based study on incidence, management and survival", BMC Cancer, 18, pp.78~ (2018)
- Hackl C, "Treatment of colorectal liver metastases in Germany : a ten-year populationbased analysis of 5772 cases of primary colorectal adenocarcinoma", BMC Cancer, 14, pp.810~ (2014)
- Kopetz S, "Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy", J Clin Oncol, 27, pp.3677~3683 (2009)
- Manfredi S, "Epidemiology and management of liver metastases from colorectal cancer", Ann Surg, 244, pp.254~259 (2006)
- Folprecht G, "Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab : the CELIM randomised phase 2 trial", Lancet Oncol, 11, pp.38~47 (2010)
- Choti MA, "Trends in long-term survival following liver resection for hepatic colorectal metastases", Ann Surg, 235, pp.759~766 (2002)
- Minagawa M, "Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer : long-term results", Ann Surg, 231, pp.487~499 (2000)
- Van Cutsem E, "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer", Ann Oncol, 27, pp.1386~1422 (2016)
- Glassberg MB, "Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases : a systematic review and meta-analysis", Onco Targets Ther, 12, pp.6407~6438 (2019)
- Ahmed M, "Image-guided tumor ablation : standardization of terminology and reporting criteria--a 10-year update", Radiology, 273, pp.241~260 (2014)
- Puijk RS, "Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation : results of the SIO and DATECAN initiative", Radiology, 301, pp.533~540 (2021)
- Crocetti L, "Quality improvement guidelines for radiofrequency ablation of liver tumours", Cardiovasc Intervent Radiol, 33, pp.11~17 (2010)
- Nieuwenhuizen S, "Resectability and ablatability criteria for the treatment of liver only colorectal metastases : multidisciplinary consensus document from the COLLISION trial group", Cancers(Basel), 12, pp.1779~ (2020)
- Correa-Gallego C, "A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases", Ann Surg Oncol, 21, pp.4278~4283 (2014)
- Vogl TJ, "Thermal ablation of liver metastases from colorectal cancer : radiofrequency, microwave and laser ablation therapies", Radiol Med, 119, pp.451~461 (2014)
- Ruers T, "Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases : a randomized EORTC Intergroup phase II study(EORTC 40004)", Ann Oncol, 23, pp.2619~2626 (2012)
- Meijerink MR, "Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases : a systematic review and meta-analysis", Cardiovasc Intervent Radiol, 41, pp.1189~1204 (2018)
- van Amerongen MJ, "Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases-a meta-analysis", HPB(Oxford), 19, pp.749~756 (2017)
- Ruers T, "Local treatment of unresectable colorectal liver metastases : results of a randomized phase II trial", J Natl Cancer Inst, 109, pp.djx015~ (2017)
- Hof J, "Outcomes after resection and", or radiofrequency ablation for recurrence after treatment of colorectal liver metastases, 2016, pp.103, 1055~1062
- Benson AB, "Colon cancer, version 2. 2021, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 19, pp.329~359 (2021)
- Dijkstra M, "Primary tumor sidedness, RAS and BRAF mutations and MSI status as prognostic factors in patients with colorectal liver metastases treated with surgery and thermal ablation : results from the Amsterdam Colorectal Liver Met Registry(Am-CORE)", Biomedicines, 9, pp.962~ (2021)
- Zhou F, "Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation?-lessons from 10 years' experience", Oncotarget, 8, pp.100791~100800 (2017)
- Gu Y, "Does the site of the primary affect outcomes when ablating colorectal liver metastases with radiofrequency ablation?", Cardiovasc Intervent Radiol, 41, pp.912~919 (2018)
- Shady W, "Percutaneous radiofrequency ablation of colorectal cancer liver metastases : factors affecting outcomes--a 10-year experience at a single center", Radiology, 278, pp.601~611 (2016)
- Merkel S, "Distant metastases in colorectal carcinoma : a proposal for a new M1 subclassification", Eur J Surg Oncol, 42, pp.1337~1342 (2016)
- Han K, "A single-center retrospective analysis of periprocedural variables affecting local tumor progression after radiofrequency ablation of colorectal cancer liver metastases", Radiology, 298, pp.212~218 (2021)
- Brouwer NPM, "An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients", Int J Cancer, 143, pp.2758~2766 (2018)
- Gillams A, "Thermal ablation of colorectal liver metastases : a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013", Eur Radiol, 25, pp.3438~3454 (2015)
- Puijk RS, "Colorectal liver metastases : surgery versus thermal ablation(COLLISION)-a phase III single-blind prospective randomized controlled trial", BMC Cancer, 18, pp.821~ (2018)